3 Stocks I Saw on T...
Health Care: Drugs
Akorn Inc. (AKRX: NASDAQ)
$13.75 0.45 | 3.38%
06/04/12 - 02:55 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 13.30 |
| 52 Week High | 13.98 |
| 52 Week Low | 6.18 |
| Avg. Daily Vol. (Mil) | 1.13 |
| Beta (3 year) | 0.22 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,264.77 |
| Shares Out (Mil) | 95.10 |
| Float (Mil) | 67.90 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 1.80 |
| Current Ratio | 3.30 |
| LT Debt/ Equity | 0.69 |
| Total Debt / Equity | 0.69 |
| Valuation Ratios | |
| Price Earnings | 30.90 |
| Price/Sales | 7.75 |
| Price/Book | 7.54 |
| Price/Cash Flow | 22.80 |
| Per Share Data | |
| Earnings | 0.43 |
| Sales | 1.72 |
| Book Value | 1.76 |
| Cash Flow | 0.58 |
| Business Summary | |
|---|---|
| Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. | |
| General Information | |
| 1925 W. Field Court
Suite 300 Lake forest, IL 60045 |
|
| www.akorn.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 553 | |
| CEO: Rajat Rai | |
| Short Interest | |
| Current Month (Mil) | 10.47 |
| Previous Month (Mil) | 9.40 |
| Short Interest Ratio (Days) | 10.10 |
| Management Effectiveness | |
| Return on Equity | 27.20 |
| Return on Assets | 14.10 |
| Return on Investments | 16.10 |
| Profitability | |
| Gross Margin | 63.20 |
| EBIT Margin | 33.80 |
| Profit Margin | 28.00 |
Portfolios with AKRX
- Portfolio NameUser Type
- UserGFNN Stockdiagnostics 16
- UserGFNN Stockdiagnostics 11
- Userpharmacy
- UserGFNN Stockdiagnostics 4
- UserDIGGITY PORTFOLIO
- UserGFNN Stockdiagnostics
- ContributorStocks At New 52-Week Highs...
- UserDivatrades
- Contributor5 Stocks Under-$10 Setting ...
- UserMister 600
Latest AKRX Headlines from TheStreet
- Akorn Stock Hits New 52-Week High (AKRX) 05.30.12 | 02:05 pm
- 3 Stocks Hit 52-Week Highs 05.15.12 | 02:05 pm
- Akorn Stock Hits New 52-Week High (AKRX) 05.15.12 | 09:05 am
- Akorn Reaches New 52-Week High (AKRX) 02.29.12 | 10:02 am
- Akorn Rises On Unusually High Volume (AKRX) 02.13.12 | 04:02 pm
- 3 Stocks Hitting 52-Week Highs: Akorn, Sunoco Logistics, Cincinnati Financial 02.10.12 | 02:02 pm
- Akorn Reaches New 52-Week High (AKRX) 02.10.12 | 12:02 pm
- Akorn Reaches New 52-Week High (AKRX) 02.01.12 | 09:02 am
- Akorn Reaches New 52-Week High (AKRX) 12.19.11 | 10:12 am
- 6 Stocks at New 52-Week Highs 12.13.11 | 01:12 pm
Press Releases for AKRX
- Akorn Reports Record First Quarter 2012 Financial Results - Business Wire 05.08.12 | 06:05 am
- Akorn Announces The Approval And Launch Of Generic Vancocin® - Business Wire 04.10.12 | 06:04 am
- Brinson Patrick Securities Initiates Research Coverage Of Akorn, Inc. - PR Newswire 03.22.12 | 03:03 pm
- Akorn Reports 2011 Fourth Quarter And Year-End Financial Results - Business Wire 03.06.12 | 07:03 am
- Akorn Announces The Appointment Of Dr. Adrienne Graves, Ph.D. To Its Board Of Directors - Business Wire 03.05.12 | 08:03 pm
- Akorn Completes The Acquisition Of Certain Assets Of Kilitch Drugs In India - Business Wire 02.28.12 | 07:02 pm
- Akorn Provides Financial Guidance For 2012 - Business Wire 01.17.12 | 07:01 am
- Akorn Acquires Three Hospital-Based Branded Injectables From Lundbeck - Business Wire 12.22.11 | 01:12 pm
- Akorn Reports Record Third Quarter 2011 Financial Results - Business Wire 11.01.11 | 07:11 am
- Akorn Enters Into An Agreement To Acquire Certain Assets Of Kilitch Drugs In India - Business Wire 10.06.11 | 12:10 am
Partner Headlines for AKRX
- Zacks Releases Four Powerful ''Buy'' Stocks: BE Aerospace, Yum! Brands, Akorn and H.B. Fuller - Press Releases - Zacks 02.08.12 | 09:02 am
- Akorn, Inc. - Momentum - Zacks 02.08.12 | 01:02 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 01.20.12 | 09:01 am
- End-of-Day Market Summary for December 23, 2011 - Benzinga 12.23.11 | 04:12 pm
- Hearing Akorn Recent Weakness Attributed to FDA Inspection Letter - Benzinga 12.23.11 | 11:12 am
- Akorn Acquires Three Hospital-Based Branded Injectables from Lundbeck; Expected To Add Approximately $30-$35M in 2012 - Benzinga 12.22.11 | 01:12 pm
- Piper Jaffray Maintains Overweight, $12 Target on Akorn - Benzinga 12.15.11 | 09:12 am
- Akorn, Inc - Aggressive Growth - Zacks 11.11.11 | 01:11 am
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- These NASDAQ Rockets Should Be In Your Portfolio - Seeking Alpha 10.19.11 | 09:10 am
